Tony Chen
Partner
Jones Day
Personal Profile
Tony Chen is a partner at Jones Day Shanghai office. He has represented a broad range of life science clients in complex cross-border intellectual property matters relating to China since 2004, including Abbvie, Biogen, BioMarin, Celgene, Helsinn, Hengrui, Hua Medicine, GeneScience, Sanofi, Sequoia Capital China, and Zensun.
Tony has led Jones Day's China IP team and local counsel in representing multinational pharmaceutical companies in patent invalidation and infringement disputes before China's patent reexamination board and IP courts. He has guided operating companies and investors in navigating China's myriad regulations relating to technology import and export, high and new technology enterprises, cybersecurity, foreign patent filing, and human genetic materials.
Tony represents Chinese biotechnology clients in licensing technology and creating IP assets on a worldwide basis. Life science venture capital investors seek assistance from Tony for analyzing and mitigating IP risks in cross-border investment in biotechnology companies. Tony has worked with Jones Day's litigators in the United States and Europe in representing Chinese entrepreneurs and companies in litigation involving patent infringement, ITC 337 investigation, trade secret misappropriation, and economic espionage prosecution.
Tony was trained as a molecular biologist before studying law. He practiced patent law in California for more than a decade before moving to Shanghai. He was an in-house counsel for a leading specialty pharmaceutical company in California and a co-founder of a drug discovery technology company in Silicon Valley.
Tony is a leader in promoting strong IP protection regimes in China for pharmaceutical innovation, including patent linkage, patent term restoration, and regulatory data protection. He is co-chair of the IP task force of Bayhelix and an advisory member of the U.S. –China IP Cooperation Dialogue organized by the U.S. Chamber of Commerce and Renmin University of China. He was co-chair of the IP subcommittee of the American Chamber of Commerce in Shanghai and an advisor to Shanghai Pudong New Area and Suzhou BioBay on the development of biotechnology industry.
Tony has led Jones Day's China IP team and local counsel in representing multinational pharmaceutical companies in patent invalidation and infringement disputes before China's patent reexamination board and IP courts. He has guided operating companies and investors in navigating China's myriad regulations relating to technology import and export, high and new technology enterprises, cybersecurity, foreign patent filing, and human genetic materials.
Tony represents Chinese biotechnology clients in licensing technology and creating IP assets on a worldwide basis. Life science venture capital investors seek assistance from Tony for analyzing and mitigating IP risks in cross-border investment in biotechnology companies. Tony has worked with Jones Day's litigators in the United States and Europe in representing Chinese entrepreneurs and companies in litigation involving patent infringement, ITC 337 investigation, trade secret misappropriation, and economic espionage prosecution.
Tony was trained as a molecular biologist before studying law. He practiced patent law in California for more than a decade before moving to Shanghai. He was an in-house counsel for a leading specialty pharmaceutical company in California and a co-founder of a drug discovery technology company in Silicon Valley.
Tony is a leader in promoting strong IP protection regimes in China for pharmaceutical innovation, including patent linkage, patent term restoration, and regulatory data protection. He is co-chair of the IP task force of Bayhelix and an advisory member of the U.S. –China IP Cooperation Dialogue organized by the U.S. Chamber of Commerce and Renmin University of China. He was co-chair of the IP subcommittee of the American Chamber of Commerce in Shanghai and an advisor to Shanghai Pudong New Area and Suzhou BioBay on the development of biotechnology industry.
